Ranbaxy Mengumumkan Inisiatif Peningkatan Standar Bisnis dan Jaminan Mutu

AsiaNet 53108

TOKYO, 22 Mei 2013 /Kyodo JBN-AsiaNet/ — Ranbaxy Laboratories Limited
(Ranbaxy), anak perusahaan Daiichi Sankyo Co., Ltd. (Daiichi Sankyo), pada
tanggal 22 Mei, mengumumkan bahwa Ranbaxy telah melewati beberapa tahun
terakhir ini untuk memperbaiki kesalahan di masa lalu akibat tindakan manajemen
terdahulu.
(http://www.daiichisankyo.com/media_investors/media_relations/press_releases/ind
ex.html)

Daiichi Sankyo terus mendukung Ranbaxy dalam usahanya mengatasi dan
memperbaiki kesalahan di masa lalu yang berakibat investigasi oleh Kementerian
Hukum (DOJ) dan Badan Pengawas Makanan dan Obat-obatan (FDA) Amerika Serikat.
Usaha-usaha ini meliputi perubahan signifikan dalam tubuh manajemen, kebiasaan,
pelaksanaan, dan kepatuhan terhadap peraturan Ranbaxy.

Daiichi Sankyo yakin bahwa segelintir pemegang saham Ranbaxy merahasiakan
dan menyalahpahami informasi penting yang berkaitan dengan investigasi DOJ dan
FDA. Daiichi Sankyo kini tengah memperjuangkan pemulihan nama baiknya secara
hukum dan belum bisa berkomentar lebih banyak saat ini terkait permasalahan ini.

Tentang Daiichi Sankyo Co., Ltd.
Terdaftar: Nomor Kode: 4568, Seksi Pertama Bursa Efek Tokyo, Osaka, dan
Nagoya.
Presiden dan CEO: Joji Nakayama

Sumber: Daiichi Sankyo Co., Ltd.

Kontak:
Noriaki Ishida
Pejabat Korporasi dan Wakil Presiden
Departemen Komunikasi Korporasi
Daiichi Sankyo Co., Ltd.
Tel: +81-3-6225-1126
e-mail: kondo.toshiya.cj@daiichisankyo.co.jp
http://www.daiichisankyo.com/


Ranbaxy Announces Improved Business Standards and Quality Assurance Initiatives

TOKYO, May 22 (ANTARA/Kyodo JBN-AsiaNet) —

Ranbaxy Laboratories Limited (hereafter, Ranbaxy), a subsidiary of Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo), announced on May 22 the actions that Ranbaxy has taken in recent years to address past conduct under prior management (http://www.daiichisankyo.com/media_investors/media_relations/press_releases/index.html).

Daiichi Sankyo continues to support Ranbaxy in its efforts to address and correct the conduct of the past which led to the investigations by the U.S. Department of Justice (“DOJ”) and the U.S. Food and Drug Administration (“USFDA”). These efforts include significant changes to Ranbaxy’s management, culture, operations and compliance.

Daiichi Sankyo believes that certain former shareholders of Ranbaxy concealed and misrepresented critical information concerning the U.S. DOJ and FDA investigations. Daiichi Sankyo is currently pursuing its available legal remedies and cannot comment further on the subject at this time.

About Daiichi Sankyo Co., Ltd.
Listed: Code No.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges
President and CEO: Joji Nakayama

Source: Daiichi Sankyo Co., Ltd.

Contact:
Noriaki Ishida
Corporate Officer & Vice President
Corporate Communications Department
Daiichi Sankyo Co., Ltd.
Tel: +81-3-6225-1126
e-mail: kondo.toshiya.cj@daiichisankyo.co.jp
http://www.daiichisankyo.com/